Patents Assigned to AstraZeneca
  • MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS
    Publication number: 20090325957
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
    Type: Application
    Filed: August 22, 2007
    Publication date: December 31, 2009
    Applicant: ASTRAZENECA AB
    Inventor: Maurice Raymond Verschoyle Finlay
  • TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
    Publication number: 20090324601
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: August 2, 2007
    Publication date: December 31, 2009
    Applicant: AstraZeneca AB
    Inventors: David Charles Blakey, Susan Ann Cartlidge, Ian Foltz, Jaspal Singh Kang, Laura Taylor, Gadi Gazit-Bornstein, Naomi Laing
  • Novel Compounds 148
    Publication number: 20090318517
    Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
    Type: Application
    Filed: June 23, 2009
    Publication date: December 24, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Branalt, David Gustafsson, Ingemar Nilsson, Magnus Polla
  • New Pyridine Analogues V
    Publication number: 20090318464
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: December 24, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kay Brickmann, Fabrizio Giordanetto, Johan Johansson, Fredrik Zetterberg
  • COMPOSITION AND PROCESS - 356
    Publication number: 20090318434
    Abstract: There is provided a process for the preparation of a compound of Formula 1, the use of said process in the preparation of a compound of Formula 5 or a phosphate, sulphate, hydrogensulphate, malate, citrate, tartrate or fumarate salt thereof, and the use of the fumarate salt in a composition for use in therapy.
    Type: Application
    Filed: June 18, 2009
    Publication date: December 24, 2009
    Applicant: AstraZeneca AB
    Inventors: Helen Blade, Gwydion Huw Churchill, Angela Charlotte Currie, Benjamin Charles Dobson, Martin Neal Kenworthy, Lyn Powell, Steven Anthony Raw, Peter Samuel Hynes
  • DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424
    Publication number: 20090318415
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 24, 2009
    Applicant: AstraZeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James M. Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • PYRAZOLE COMPOUNDS 436
    Publication number: 20090318468
    Abstract: There is provided novel compounds of formula (Ia) or (Ib): or pharmaceutically acceptable salsts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 24, 2009
    Applicant: AstraZeneca AB
    Inventors: David Buttar, Maria-Elena Theoclitou, Andrew Peter Thomas
  • N-(2-AMINIPHENYL)-4-(5-((ETHYLAMINO)METHYL)-1,2-THIAZOL-2-YL) BENZAMIDE AND N-(2-AMINOPHENYL)-4-(5-((ISOPROPYLAMINO)METHYL)-1,2-THIAZOL-2-YL) BENZAMIDE AS HDAC INHIBITORS
    Publication number: 20090312556
    Abstract: The invention concerns novel benzamide compounds of Formula (I): wherein R wherein is ethyl or isopropyl; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).
    Type: Application
    Filed: December 15, 2005
    Publication date: December 17, 2009
    Applicant: ASTRAZENECA R& D ALDERLY
    Inventors: Elaine Sophie, Elizabeth Stokes, Gregory Carr
  • DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS
    Publication number: 20090312336
    Abstract: Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.
    Type: Application
    Filed: May 16, 2007
    Publication date: December 17, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Iain Simpson, Richard Andrew Ward
  • METHODS FOR CANCER TREATMENT USING TAK1 INHIBITORS
    Publication number: 20090312396
    Abstract: The invention includes, in part, a method of inhibiting lymphoid tumour cell proliferation by contacting the lymphoid with a TAK1 inhibitor.
    Type: Application
    Filed: July 10, 2006
    Publication date: December 17, 2009
    Applicant: AstraZeneca AB
    Inventors: Kate Byth, Sangeetha Palakurthi, Lihua Yu, Qi Zang
  • Methods for Identifying FZD8 Modulators and the Use of such Modulators for Treating Osteoarthritis
    Publication number: 20090311243
    Abstract: Methods and kits for identifying agents that modulate the function of the Methods and kits for identifying agents that modulate the function of the receptor Fzd8 are provided. Accordingly, the present invention makes available methods for identifying agents useful as modulators of Wnt-Fzd8 signalling. Therapeutic uses of the identified agents for treating osteoarthitis are also provided.
    Type: Application
    Filed: May 29, 2006
    Publication date: December 17, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Sarah Brockbank, Peter Newham
  • Pyridine Analogues IV
    Publication number: 20090312368
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: July 2, 2007
    Publication date: December 17, 2009
    Applicant: ASTRAZENECA AB
    Inventor: Johan Johansson
  • Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3
    Publication number: 20090312322
    Abstract: The present invention relates to a new use of oxindole derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof, [Chemical formula should be inserted here. Please see paper copy.] wherein R1, R2, R3, m and n are as defined as in claim 1, as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3.
    Type: Application
    Filed: December 9, 2008
    Publication date: December 17, 2009
    Applicant: AstraZeneca AB
    Inventors: Stefan Berg, Ratan Bhat, Philip Edwards, Sven Hellberg
  • CHEMICAL COMPOUNDS
    Publication number: 20090312372
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Application
    Filed: August 14, 2009
    Publication date: December 17, 2009
    Applicant: AstraZeneca AB
    Inventors: William MCCOULL, Martin PACKER, James Stewart SCOTT, Paul Robert Owen WHITTAMORE
  • Quinazoline compounds for the treatment of hyperproliferative disorders
    Patent number: 7632840
    Abstract: A quinazoline derivative of the formula I: wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula I, are useful in the treatment of hyperproliferative disorders such as a cancer.
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: December 15, 2009
    Assignee: AstraZeneca AB
    Inventors: Benedicte Delouvrie, Craig Steven Harris, Laurent Francois Andre Hennequin, Christopher Thomas Halsall, Janet Elizabeth Pease, Peter Mark Smith
  • Indole Derivatives
    Publication number: 20090306126
    Abstract: The invention concerns indole derivatives of Formula I or pharmaceutically-acceptable salts thereof, wherein each of Ring A, m, R1, R2, n, R3 and G1 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.
    Type: Application
    Filed: May 18, 2007
    Publication date: December 10, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Michael Foote, Edward Jolyon Griffen
  • PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY
    Publication number: 20090306116
    Abstract: A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.
    Type: Application
    Filed: September 13, 2006
    Publication date: December 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Andrew Peter Thomas, Robin Wood
  • Assays for Allosteric Modulators of G-Protein Coupled Receptors (GPCRs)
    Publication number: 20090305321
    Abstract: The present invention relates to G protein-coupled receptors (GPCRs) and allosteric modulators thereof. More specifically, the invention relates to allosteric modulators of GPCRs that interact at an intracellular binding site. It also relates to methods for designing or identifying small molecule allosteric modulators, including assays (such as competitive binding assays) and methods employing a homology model for the GPCR intracellular site.
    Type: Application
    Filed: March 22, 2006
    Publication date: December 10, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Caroline Grahames, Philip Mallinder, Fraser McIntosh, Nicholas Tomkinson, Tracey Wright
  • Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286
    Publication number: 20090306158
    Abstract: Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 3, 2009
    Publication date: December 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Joseph Cacciola, James Empfield, James Folmer, Angela M. Hunter, Scott Throner
  • CHEMICAL COMPOUNDS
    Publication number: 20090306075
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Application
    Filed: August 14, 2009
    Publication date: December 10, 2009
    Applicant: AstraZeneca AB
    Inventors: William MCCOULL, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore